Soticlestat
DrugSoticlestat tablets or mini-tablets.
Other names: TAK-935
NCT Number: NCT03635073
The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment.
Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study.
Study treatments may continue as long as the participant is receiving benefit from it.
Looking for future studies?
Notify Me2 year and older
All sexes
Interventional
Phase 2
Monash Children's Hospital, Clayton, Victoria, Australia
The drug being tested in this study is called soticlestat (TAK-935). This global, open-label extension (OLE) study will assess the long-term safety and tolerability of soticlestat in participants with developmental and epileptic encephalopathy (DEE) who participated in previous short-term efficacy/safety studies of soticlestat. All participants will receive Soticlestat treatment.
Participants who rollover from previous blinded study will undergo up to 2 weeks of Dose Optimization Period (depending on the previous study) followed by Maintenance Period. Participants who rollover from an open-label study will continue on their current dose until development is stopped by the sponsor, or the product is approved for marketing, or at any time at the discretion of the sponsor. There will be a 4-week Safety Follow-up Period after the last dose in Maintenance Period, including a 2-week dose Tapering Period.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Soticlestat tablets or mini-tablets.
Other names: TAK-935
Time frame: From screening up to end of the study (up to approximately 84 months)
An Adverse Event (AE) was defined any untoward medical occurrence in a subject or clinical study subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign vital sign, symptom, or disease temporally associated with the use of a medicinal product, whether considered related to this medicinal product. A TEAE is defined as any AE that starts or increases in severity during or after the first dose of study drug.
Time frame: Baseline, Week 338
VABS,3rd edition,Parent Caregiver Form:parent-report questionnaire of adaptive functioning/how is individual's routine behaviour at home & in community.4 domains(Communication,Daily Living,Social Skills&Relationships,Problem Behaviors) contained 12 subdomains including items(each scored 0-2).Subdomain scores=sum of item scores within that subdomain.Ranges of subdomain scores are:Communication:Listening&Understanding(0-78);Talking(0-98);Reading&Writing(0-76),Daily Living:Caring for Self(0-110);Caring for Home(0-60);Living in Community(0-116),Social Skills&Relationships:Relating to Others(0-86);Playing&Using Leisure Time(0-72);Adapting(0-66),Problem Behaviors:Section A(0-26);Section B(0-22),Section C(0-40).For 1st 3 domains,higher subdomain scores=higher adaptive functioning,positive CFB=improvement.For Problem Behaviors,higher subdomain scores=more problem behaviors,negative CFB=improvement(reduction in problem behaviors).No subdomain scores combined to compute any total score.
Time frame: Baseline, Week 338
The ABC-C measures psychiatric symptoms and behavioral disturbance exhibited by individuals across 5 subscales with 58 items: Irritability subscale (15 items); Lethargy/Social Withdrawal subscale (16 items); Stereotypic Behavior subscale (7 items); Hyperactivity subscale (16 items); and Inappropriate Speech subscale (4 items). Each item is rated on a scale of 0 to 3 ("not at all a problem" to "the problem is severe in degree"). The total score was calculated by summing the scores on all 58 items where the total scores ranged from 0 to 174. Higher scores indicate more severity in psychiatric symptoms and behavioral disturbance. Negative change from baseline scores represents improvement. Positive change from baseline scores represents worsening.
Time frame: Baseline, Week 338
The ABC-C measures psychiatric symptoms and behavioral disturbance exhibited by individuals across 5 subscales with 58 items: Irritability subscale (15 items: Ranges from 0 to 45); Lethargy/Social Withdrawal subscale (16 items: Ranges from 0 to 48); Stereotypic Behavior subscale (7 items: Ranges from 0 to 21); Hyperactivity subscale (16 items: Ranges from 0 to 48); and Inappropriate Speech subscale (4 items: Ranges from 0 to 12). Each item is rated on a scale of 0 to 3 ("not at all a problem" to "the problem is severe in degree"). Subscale scores are calculated as the sum of items within the subscale. Higher subscale scores indicate more severity in psychiatric symptoms and behavioral disturbance. Negative change from baseline score represents improvement. Positive change from baseline score represents worsening.
Time frame: Baseline, Week 338
Suicidal ideation and behavior was assessed in participants with at least 6 years of age using the C-SSRS. The C-SSRS is a 3-part scale that measures suicidal ideation (eg, participants endorses thoughts about a wish to be dead or has other thoughts of suicide), intensity of ideation (frequency), and suicidal behavior (actually, interrupted, and aborted attempts at suicide). SI=Suicidal Ideation; SB=Suicidal Behavior and NSSJB=Non-suicidal Self-injurious Behavior for the categories reported. BL denotes Baseline, V denotes Visit and W denotes Week in the categories.
Time frame: Baseline, Week 338
BL denotes Baseline, CFB denotes Change from Baseline and W denotes Week for the reported categories.
Time frame: Baseline, Week 338
BL denotes Baseline, CFB denotes Change from Baseline and W denotes Week for the reported categories.
Time frame: Baseline, Week 338
BL denotes Baseline, CFB denotes Change from Baseline and W denotes Week for the reported categories.
Time frame: Baseline, Week 338
BL denotes Baseline, CFB denotes Change from Baseline, W denotes Week, HDL denotes High Density Lipid and LDL denotes Low Density Lipid for the reported categories.
Time frame: Baseline, Week 338
BL denotes Baseline, CFB denotes Change from Baseline and W denotes Week for the reported categories.
Time frame: Baseline, Week 338
The percentage of the specified blood cells relative to total leukocyte count was determined and reported. BL denotes Baseline, CFB denotes Change from Baseline and W denotes Week for the reported categories.
Time frame: Baseline, Week 338
BL denotes Baseline, CFB denotes Change from Baseline and W denotes Week for the reported categories.
Time frame: Baseline, Week 338
BL denotes Baseline, CFB denotes Change from Baseline and W denotes Week for the reported categories.
Time frame: Baseline, Week 338
BL denotes Baseline, CFB denotes Change from Baseline and W denotes Week for the reported categories.
Time frame: Baseline, Week 338
BL denotes BL, CFB denotes Change from baseline and W denotes Week for the reported categories.
Time frame: Baseline, Week 338
Time frame: Baseline, Week 338
Time frame: Baseline, Week 338
Time frame: Baseline, Week 338
Time frame: Baseline, Week 338
Time frame: Baseline, Week 338
Time frame: Baseline, Week 338
Time frame: Baseline, Week 338
Time frame: Baseline, Week 338
Time frame: Baseline, Week 338
Time frame: Baseline to Week 338
ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, HGB: Hemoglobin, ULN: Upper limit of normal, LLN: Lower limit of normal and UREAN: Urea Nitrogen for the specified categories. mmol/L indicates millimoles per liter. Data is reported only for participants who had potentially clinically significant values.
Time frame: Baseline to Week 338
Data is reported only for participants who had potentially clinically significant values.
Time frame: Baseline to Week 338
The criteria for defining clinical significance for weight category was the participants less than equal to (<=)10 years of age with weight below minus (-)2standard deviation (SD) of the median weight of the same age and gender per world health organization (WHO) growth chart and for height category was the participants less than (<)18 years of age with height below -2SD of the median weight of the same age and gender per WHO growth chart.
Time frame: Baseline to Week 338
Time frame: Baseline, Week 252
Change from Baseline is denoted as CFB.
Time frame: Baseline, Week 252
Change from Baseline is denoted as CFB.
Time frame: Baseline, Week 252
Change from Baseline is denoted as CFB.
Time frame: Baseline, Week 252
Time frame: Baseline, Week 336
CGI-S is used to obtain an assessment of symptom severity, focusing on clinicians' observations of the subject's current cognitive, functional, and behavioral performance. The CGI-S is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (among the most severely ill participants). BL denotes BL, CFB denotes Change from baseline and W denotes Week for the reported categories.
Takeda
Industry
A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Subjects With Developmental Epileptic Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome (ENDYMION 1)
Acronym: Endymion 1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02224573
Brain Diseases, Central Nervous System Diseases
View Trial DetailsNCT03650452
Brain Diseases, Brain Ischemia
Phoenix, Arizona, United States
View Trial DetailsNCT07568860
Brain Diseases, Central Nervous System Diseases
View Trial DetailsNCT07013331
Brain Diseases, Central Nervous System Diseases
Bron, Rhone, France
View Trial Details